Compare Gilead Sciences, Inc. (GILD) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MasterCard Inc — how do they compare? Gilead Sciences, Inc. trades at $150.31 (market cap $182.40B), while MasterCard Inc trades at $586.64 (market cap $503.50B). The key difference: MasterCard Inc is far larger — about 2.8× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and MasterCard Inc for 134 Days on average.
| GILD | MA | |
|---|---|---|
Market Cap | $182.40B | $503.50B |
Volume | 4,469,821 | 3,390,859 |
Sector | Health | Financials |
52-Week High | $155.80 | $599.86 |
52-Week Low | $116.74 | $471.55 |
Typical Hold Time | 111 Days | 134 Days |
Enterprise Value | $205.46B | $516.53B |
Dividend Yield | 2.23% | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Mastercard (MA) trades at $585.52, up 2.71% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue of $32.79B, net income margin of 46.34%, and impressive ROE of 241.49%. Recent institutional buying activity and positive analyst sentiment (80% buy ratings) support the stock's momentum as it approaches key resistance levels.
Mastercard presents a compelling growth opportunity with expanding digital payment adoption and strong financial performance, though elevated valuation multiples (P/E 31.6, P/S 14.7) and emerging payment technology competition warrant monitoring. The consensus price target of $666.67 suggests 14% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
